KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Payables (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Payables for 15 consecutive years, with $107.8 million as the latest value for Q4 2025.

  • Quarterly Payables rose 41.19% to $107.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $107.8 million through Dec 2025, up 41.19% year-over-year, with the annual reading at $107.8 million for FY2025, 41.19% up from the prior year.
  • Payables for Q4 2025 was $107.8 million at Supernus Pharmaceuticals, down from $108.6 million in the prior quarter.
  • The five-year high for Payables was $498.3 million in Q4 2022, with the low at $70.1 million in Q1 2021.
  • Average Payables over 5 years is $130.1 million, with a median of $82.8 million recorded in 2023.
  • The sharpest move saw Payables soared 2143.89% in 2021, then plummeted 84.03% in 2023.
  • Over 5 years, Payables stood at $117.7 million in 2021, then skyrocketed by 323.43% to $498.3 million in 2022, then tumbled by 84.03% to $79.6 million in 2023, then decreased by 4.04% to $76.4 million in 2024, then surged by 41.19% to $107.8 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $107.8 million, $108.6 million, and $77.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.